Literature DB >> 9989822

Characteristics of genomic breakpoints in TLS-CHOP translocations in liposarcomas suggest the involvement of Translin and topoisomerase II in the process of translocation.

H Kanoe1, T Nakayama, T Hosaka, H Murakami, H Yamamoto, Y Nakashima, T Tsuboyama, T Nakamura, D Ron, M S Sasaki, J Toguchida.   

Abstract

Fusion of TLS/FUS and CHOP gene by reciprocal translocation t(12;16)(q32;q16) is a common genetic event found in myxoid and round-cell liposarcomas. Characterization of this genetic event was performed by three methods, Southern blot, RT-PCR, and genomic long-distance PCR in nine myxoid and three round-cell liposarcomas. All but one tumors showed genetic alternations indicating the fusion of TLS/FUS and CHOP gene. Two novel types of fusion transcripts were found, of which one lacked exon 2 sequence of CHOP gene, and the other lacked 3' half of exon 5 of TLS gene. The latter case was caused by a cryptic splicing site which was created by the genomic fusion. Detailed analyses genomic fusion points revealed several sequence characteristics surrounding the fusion points. Homology analyses of breakpoint sequences with known sequence motifs possibly involve in the process of translocation uncovered Translin binding sequences at both of TLS/ FUS and CHOP breakpoints in two cases. Translocations were always associated with other genetic alterations, such as deletions, duplications, or insertions. Short direct repeats were almost always found at both ends of deleted or duplicated fragments some of which had apparently been created by joining of sequences that flank the rearrangement. Finally, consensus topoisomerase II cleavage sites were found at breakpoints in all cases analysed, suggesting a role of this enzyme in creating staggered ends at the breakpoint. These data suggested that sequence characteristics may play an important role to recruit several factors such as Translin and topoisomerase II in the process of chromosomal translation in liposarcomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989822     DOI: 10.1038/sj.onc.1202364

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma.

Authors:  Taisuke Hosaka; Yasuaki Nakashima; Katsuyuki Kusuzaki; Hiroaki Murata; Tomitaka Nakayama; Takeharu Nakamata; Tomoki Aoyama; Takeshi Okamoto; Kohichi Nishijo; Nobuhito Araki; Tadao Tsuboyama; Takashi Nakamura; Junya Toguchida
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

2.  Molecular characterization of the pericentric inversion that causes differences between chimpanzee chromosome 19 and human chromosome 17.

Authors:  Hildegard Kehrer-Sawatzki; Bettina Schreiner; Simone Tänzer; Matthias Platzer; Stefan Müller; Horst Hameister
Journal:  Am J Hum Genet       Date:  2002-07-01       Impact factor: 11.025

3.  Identification of sequence motifs at the breakpoint junctions in three t(1;9)(p36.3;q34) and delineation of mechanisms involved in generating balanced translocations.

Authors:  Marzena Gajecka; Adam Pavlicek; Caron D Glotzbach; Blake C Ballif; Malgorzata Jarmuz; Jerzy Jurka; Lisa G Shaffer
Journal:  Hum Genet       Date:  2006-07-18       Impact factor: 4.132

4.  Unexpected complexity at breakpoint junctions in phenotypically normal individuals and mechanisms involved in generating balanced translocations t(1;22)(p36;q13).

Authors:  Marzena Gajecka; Andrew J Gentles; Albert Tsai; David Chitayat; Katherine L Mackay; Caron D Glotzbach; Michael R Lieber; Lisa G Shaffer
Journal:  Genome Res       Date:  2008-09-02       Impact factor: 9.043

Review 5.  The TET family of proteins: functions and roles in disease.

Authors:  Adelene Y Tan; James L Manley
Journal:  J Mol Cell Biol       Date:  2009-09-24       Impact factor: 6.216

6.  Altering the GTP binding site of the DNA/RNA-binding protein, Translin/TB-RBP, decreases RNA binding and may create a dominant negative phenotype.

Authors:  V M Chennathukuzhi; Y Kurihara; J D Bray; J Yang; N B Hecht
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

7.  Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas.

Authors:  C R Antonescu; A Elahi; M Humphrey; M Y Lui; J H Healey; M F Brennan; J M Woodruff; S C Jhanwar; M Ladanyi
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

8.  Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.

Authors:  Sumati Gupta; Launce Gouw; Jennifer Wright; Sant Chawla; Debbie Pitt; Mark Wade; Ken Boucher; Sunil Sharma
Journal:  Invest New Drugs       Date:  2016-02-20       Impact factor: 3.850

9.  Genomic aberrations in lung adenocarcinoma in never smokers.

Authors:  Bastien Job; Alain Bernheim; Michèle Beau-Faller; Sophie Camilleri-Broët; Philippe Girard; Paul Hofman; Julien Mazières; Saloua Toujani; Ludovic Lacroix; Julien Laffaire; Philippe Dessen; Pierre Fouret
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

10.  Sequencing human-gibbon breakpoints of synteny reveals mosaic new insertions at rearrangement sites.

Authors:  Santhosh Girirajan; Lin Chen; Tina Graves; Tomas Marques-Bonet; Mario Ventura; Catrina Fronick; Lucinda Fulton; Mariano Rocchi; Robert S Fulton; Richard K Wilson; Elaine R Mardis; Evan E Eichler
Journal:  Genome Res       Date:  2008-11-24       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.